Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage.
PERG
brimonidine
ischemia-reperfusion
neuroprotection
retinal ganglion cells
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
07
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
To investigate the neuroprotective effect of brimonidine after retinal ischemia damage on mouse eye. Glaucoma is an optic neuropathy characterized by retinal ganglion cells (RGCs) death, irreversible peripheral and central visual field loss, and high intraocular pressure. Ischemia reperfusion (I/R) injury model was used in C57BL/6J mice to mimic conditions of glaucomatous neurodegeneration. Mouse eyes were treated topically with brimonidine and pattern electroretinogram were used to assess the retinal ganglion cells (RGCs) function. A wide range of inflammatory markers, as well as anti-inflammatory and neurotrophic molecules, were investigated to figure out the potential protective effects of brimonidine in mouse retina. In particular, brain-derived neurotrophic factor (BDNF), IL-6, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor DR-5, TNF-α, GFAP, Iba-1, NOS, IL-1β and IL-10 were assessed in mouse retina that underwent to I/R insult with or without brimonidine treatment. Brimonidine provided remarkable RGCs protection in our paradigm. PERG amplitude values were significantly (
Identifiants
pubmed: 34366858
doi: 10.3389/fphar.2021.705405
pii: 705405
pmc: PMC8333612
doi:
Types de publication
Journal Article
Langues
eng
Pagination
705405Informations de copyright
Copyright © 2021 Conti, Romano, Eandi, Toro, Rejdak, Di Benedetto, Lazzara, Bernardini, Drago, Cantarella and Bucolo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Ophthalmol. 1996 Mar;114(3):299-305
pubmed: 8600890
Mol Neurodegener. 2011 Jan 13;6(1):4
pubmed: 21232114
Retina. 2008 Apr;28(4):645-52
pubmed: 18398369
Prog Brain Res. 2020;257:155-166
pubmed: 32988470
Cell Death Dis. 2014 Jul 17;5:e1331
pubmed: 25032854
Dev Neurosci. 2011;33(6):519-30
pubmed: 22286051
Prog Retin Eye Res. 2004 Jan;23(1):91-147
pubmed: 14766318
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):65-73
pubmed: 9888428
Curr Neuropharmacol. 2018;16(7):978-992
pubmed: 28925883
J Neuroimmunol. 2014 Sep 15;274(1-2):1-13
pubmed: 25091432
Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1632-6
pubmed: 8127857
J Neuroinflammation. 2012 May 14;9:92
pubmed: 22583833
Arch Ophthalmol. 2002 Jun;120(6):797-803
pubmed: 12049586
J Neurosci. 2000 Dec 1;20(23):8693-700
pubmed: 11102475
Int Ophthalmol. 2018 Dec;38(6):2553-2562
pubmed: 29159432
Brain Res Bull. 2006 Dec 11;71(1-3):208-18
pubmed: 17113948
Cell Death Dis. 2016 Dec 8;7(12):e2514
pubmed: 27929541
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):3064-3073
pubmed: 31348824
Indian J Ophthalmol. 2014 Jun;62(6):699-701
pubmed: 25005199
Pharmacol Ther. 2011 May;130(2):191-201
pubmed: 21295073
Invest Ophthalmol Vis Sci. 2014 Aug 14;55(9):5602-9
pubmed: 25125600
Eur J Ophthalmol. 1999 Jan-Mar;9 Suppl 1:S17-21
pubmed: 10230601
J Vis Exp. 2016 Jul 14;(113):
pubmed: 27501124
PLoS One. 2014 Jul 16;9(7):e102392
pubmed: 25029531
Biochem Pharmacol. 2020 Oct;180:114199
pubmed: 32798466
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3978-83
pubmed: 9520478
Exp Eye Res. 2015 Dec;141:164-70
pubmed: 25998495
Cochrane Database Syst Rev. 2017 Jan 25;1:CD006539
pubmed: 28122126
J Immunol. 2002 Nov 1;169(9):4739-44
pubmed: 12391182
J Neurosci Res. 2005 Dec 1;82(5):674-89
pubmed: 16273539
Int J Mol Sci. 2018 Jan 13;19(1):
pubmed: 29342845
J Neurosci. 1999 May 15;19(10):3809-17
pubmed: 10234013
Curr Eye Res. 2017 Jan;42(1):125-133
pubmed: 27314704
Free Radic Biol Med. 2011 Jul 1;51(1):216-24
pubmed: 21545836
J Neuroinflammation. 2017 Jun 27;14(1):130
pubmed: 28655348
Front Pharmacol. 2015 Oct 29;6:248
pubmed: 26578958
Curr Eye Res. 2018 Jul;43(7):921-933
pubmed: 29595330
PLoS One. 2011 Mar 31;6(3):e18305
pubmed: 21483783
PeerJ. 2019 Oct 4;7:e7849
pubmed: 31592359
Nutrients. 2020 Jun 27;12(7):
pubmed: 32605122
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3444-50
pubmed: 11006237
Neurobiol Dis. 2010 Aug;39(2):138-47
pubmed: 20359534